How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,298 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

301. Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: In good general health Between 22 and 95 years of age and diagnosed with cataract(s) Able to comprehend and sign a written statement of informed consent for participation in the study, including HIPAA Undergoing cataract extraction surgery with an Alcon SN6 platform intraocular lens implantation into the posterior chamber Clear intraocular media, other than cataract Potential postoperative best-corrected visual acuity (BSCVA) of 20/30

2018 Clinical Trials

302. To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

and HIPAA authorization for the release of personal health information. NOTE: HIPAA authorization may be either included in the informed consent or obtained separately. Patients >18 years of age. Histological or cytologic proof of adenocarcinoma of the prostate. Radiographic evidence of metastatic disease by CT scan or MRI and/or bone scan. Known castration resistant prostate cancer, defined according to PCWG3 criteria. Subjects who have metastatic castration resistant prostate cancer that have

2018 Clinical Trials

303. Reproducibility of thrombus volume quantification in multicenter computed tomography pulmonary angiography studies Full Text available with Trip Pro

Reproducibility of thrombus volume quantification in multicenter computed tomography pulmonary angiography studies To evaluate reproducibility of pulmonary embolism (PE) clot volume quantification using computed tomography pulmonary angiogram (CTPA) in a multicenter setting.This study was performed using anonymized data in conformance with HIPAA and IRB Regulations (March 2015-November 2016). Anonymized CTPA data was acquired from 23 scanners from 18 imaging centers using each site's standard

2018 World journal of radiology

304. Association between albumin administration and survival in cardiac surgery: a retrospective cohort study. Full Text available with Trip Pro

Association between albumin administration and survival in cardiac surgery: a retrospective cohort study. Albumin is widely used during and after on-pump cardiac surgery, although it is unclear whether this therapy improves clinical outcomes.This observational study utilized the Cerner Health Facts® database (a large HIPAA-compliant clinical-administrative database maintained by Cerner Inc., USA) to identify a cohort of 6,188 adults that underwent on-pump cardiac surgery for valve

2018 Canadian Journal Of Anaesthesia

305. Post Approval Study of the remedē System

and actively being followed as part of the remedē System Pivotal Trial are eligible for this trial. Criteria Inclusion Criteria: Subjects who were previously implanted with the remedē System and participated in the remedē System Pivotal Trial In the investigator's opinion, willing and able to comply with all study requirements Signed Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent (including Health Insurance Portability and Accountability Act [HIPAA

2018 Clinical Trials

306. Chelation Therapy in Diabetic Patients With Critical Limb Ischemia

assessment, and noninvasive blood flow assessments will be performed at baseline, and at completion of 20 and 40 infusions. HIPAA-compliant photographs of the affected lower limbs will be taken at each infusion visit. The specific aims of this open-label pilot study are to: Assess the effect of EDTA-based chelation therapy plus vitamins in diabetic patients with below-the-knee peripheral artery disease presenting with impending amputation and determine if there is an improvement in vascular flow (...) . Additionally, for patients entering the continued treatment phase, the test will be performed during infusion visits 45 and 50. Wound Evaluation [ Time Frame: 1 Year ] HIPAA-compliant pictures of skin integrity including wounds and areas of gangrene will be obtained for each patient at baseline and every 5 infusions. Wound assessment includes ulcer measurements (length, width, depth and undermining) and percentage of epithelialization. Additionally, for patients entering the continued treatment phase

2018 Clinical Trials

307. ViBone in Cervical and Lumbar Spine Fusion

, or 3 contiguous levels between L1-S1 Patient signed Consent Form with HIPAA Authorization Appropriate candidate for surgery Patient will adhere to the scheduled follow-up visits and requirements of the protocol including routine patient exams - pre-operative, operative, and at least two post- operative visits (6 and 12 months post-surgery). Pre-operative and post-operative visits include X-ray (required) and CT scan (if available). Exclusion Criteria: Long term use of medications that are known

2018 Clinical Trials

308. Brain Injury Rehabilitation Improving the Transition Experience

, although a HIPAA-compliant video conferencing option will also be available. The content of these contacts will include: Particularly in the first few calls, review of discharge plans and assistance and/or directive problem-solving around any obstacles to following discharge plans; Assessment of unmet needs, developed into a standard checklist of areas of need that are relevant to TBI, culled from literature on need fulfillment in this population. Outcome Measures Go to Primary Outcome Measures

2018 Clinical Trials

309. Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)

greater than one hour either for clinical or research purposes within 3 hrs of the proposed PET-MRI examination. Participant will be fully informed and has personally signed and dated the written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) provisions Exclusion Criteria: Subjects for whom exposure to a strong magnetic field would be a health risk (e.g., subjects with cardiac pacemakers or non-MR compatible metallic implants) Women who are pregnant. Subjects who

2018 Clinical Trials

310. Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Prostatic Adenocarcinoma

consent and Authorization for Use and Release of Health and Research Study Information (HIPAA authorization) NOTE: HIPAA authorization may be either included in the informed consent or obtained separately Male aged 18 years and above Serum testosterone of ≥150 ng/dL (For cohorts A and B1, testosterone level requirement is exempted if they are already on ADT prior to treatment start. For cohort B2, patients will be considered eligible if their testosterone is currently ≥150 ng/dl). Histologically

2018 Clinical Trials

311. A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures; participants will be asked to give written or verbal assent according to local requirements Subject has a centrally confirmed (by TRiNDS central genetic counselor[s]) diagnosis of DMD as defined as: Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR Identifiable mutation

2018 Clinical Trials

312. Mobile Devices as Educational Skin History Tools

or other drug treatment facilities and therefore considered prisoners Patients will also be excluded if they are incompetent to provide informed consent and HIPAA authorization. If the area being operated on is of the genitals or breasts If the area being operated on is of the face, and photos of the area cannot be cropped or the eyes cannot be covered sufficiently such that photos are non-identifying Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2018 Clinical Trials

313. Post-Exercise Cardiovascular Responses Following Energy Drink Consumption

the study or consent process will be excluded from the study due to unavailability of medical qualified translator at all times during the study. If the subject refuses to sign the informed consent document or HIPAA Authorization, they will be excluded as well. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer

2018 Clinical Trials

314. Post Acute Cardiac Event Smoking (PACES) Study

: August 2018 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Plan Description: Completely de-identified data (i.e.,data that has been cleaned of all 18 types of HIPAA identifiers) will be available to other qualified researchers. Within 18 months of study completion, we will make datasets available to interested investigators who submit a written request to the PI. The only contingency on the use of the data will be that ethical guidelines be followed (e.g., only individuals

2018 Clinical Trials

315. A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging

that work in the respective urology clinics Providers may be any gender or race/ethnicity Qualitative portion only: Urology Chiefs and/or frontline staff physicians participating PAs & NPs having cared for at least 5 men with incident prostate cancer within the previous 6 months Patients will not be directly recruited into the study. The investigators have obtained a waiver of HIPAA authorization and informed consent to analyze electronic health records of patients that are diagnosed with ICD-9 code 185

2018 Clinical Trials

316. Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 12 Years to 55 Years (Child, Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Be between 12 and 55 years of age, male or female, of any race; Provide written informed consent and sign a HIPAA form. Subjects who are under the age of 18 (or have not yet reached the age of majority per local regulations) will need to sign an assent form as well

2018 Clinical Trials

317. PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

, bilateral tubal ligation, or bilateral oophorectomy) or have not been free of menses for >1 year. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 7 months after the last dose of study treatment. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may

2018 Clinical Trials

318. Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study

baseline period. Note: Each seizure within a cluster may be counted as separate seizures. 5. 12 years of age or older. 6. Subject is a male or non-pregnant female adequately protected from conception. Females of childbearing potential must use an acceptable method of birth control. 7. Provide written informed consent-assent/Health Insurance Portability and Accountability Act (HIPAA) authorization and self-reported measures with minimal assistance as determined by the investigator. Exclusion Criteria

2018 Clinical Trials

319. Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases

at the time of informed consent Ability to provide written informed consent and HIPAA authorization Platelet count > 100 k/cumm, Hgb > 7.5 gm/dL, INR < 1.3, ANC > 1.5 k/cumm Patients currently on cytotoxic chemotherapy or immunotherapy are eligible, not including anti-VEGF therapy Exclusion Criteria Patients who received anti-VEGF therapy within 6 weeks prior to enrollment, as there is increased risk of fatal brain hemorrhage with surgical resection Major medical illnesses or psychiatric impairments

2018 Clinical Trials

320. Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

More Information Go to Layout table for additonal information Responsible Party: HonorHealth Research Institute Identifier: Other Study ID Numbers: SU2C HRI NPG-002 First Posted: January 25, 2018 Last Update Posted: February 21, 2019 Last Verified: February 2019 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Yes Plan Description: If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>